(Q50968798)

26 March 2018

meta-analysis

0 references

title

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. (English)

1 reference

26 March 2018

0 references

3

1 reference

26 March 2018

author name string

Viswanath Reddy Belum

series ordinal

1

1 reference

26 March 2018

Shenhong Wu

series ordinal

2

1 reference

26 March 2018

publication date

23 May 2013

1 reference

26 March 2018

Investigational New Drugs

published in

1 reference

26 March 2018

volume

31

1 reference

26 March 2018

issue

4

1 reference

26 March 2018

page(s)

1078-1086

1 reference

26 March 2018

https://scigraph.springernature.com/pub.10.1007/s10637-013-9977-0

exact match

0 references

cites work

Predictors of competing mortality in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

21 January 2018

Regorafenib for cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Epithelial-stromal interactions in basal cell cancer: the PDGF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9977-0

A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma

21 January 2018

1 reference

12 December 2020

Expression of c-kit and kit ligand proteins in normal human tissues

1 reference

12 December 2020

The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.

1 reference

12 December 2020

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

1 reference

12 December 2020

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

12 December 2020

10.1007/S10637-013-9977-0

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018